Table 2.
Event rates (per 100 person-years) in TREAT among patients with and without retinopathy
| Event rate* (95% CI) |
Unadjusted HR (95% CI) | ||
|---|---|---|---|
| No Retinopathy N=2143 | Retinopathy N=1895 | ||
| CV composite | 13.4 (12.4 to 14.5) | 13.9 (12.8 to 15.1) | 1.04 (0.93 to 1.16) |
| Death from any cause | 8.1 (7.4 to 8.9) | 8.1 (7.3 to 8.9) | 0.99 (0.87 to 1.14) |
| CV death | 4.9 (4.3 to 5.5) | 5.4 (4.7 to 6.1) | 1.10 (0.92 to 1.31) |
| Myocardial infarction | 2.6 (2.2 to 3.1) | 2.8 (2.3 to 3.3) | 1.07 (0.83 to 1.36) |
| Stroke | 1.7 (1.3 to 2.1) | 1.6 (1.3 to 2.0) | 0.96 (0.70 to 1.32) |
| Congestive heart failure | 4.6 (4.0 to 5.2) | 5.0 (4.4 to 5.7) | 1.10 (0.91 to 1.32) |
| Renal composite (ESRD or death) | 12.2 (11.3 to 13.2) | 15.6 (14.5 to 16.8) | 1.28 (1.15 to 1.43) |
| ESRD | 5.3 (4.7 to 6.0) | 9.7 (8.8 to 10.7) | 1.83 (1.56 to 2.13) |
*Event rates are per 100 patient years. CV, cardiovascular; ESRD,end-stage renal disease; TREAT, Trial to Reduce cardiovascular Events with Aranesp Therapy.